Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced its participation in the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 11, 2023, at 10:30 a.m. PT, followed by a Q&A session at 10:50 a.m. PT. A live webcast will be available on the Company's website and can be replayed for 30 days post-event. Karyopharm is known for its SINE compound technology and its lead product, XPOVIO®, which is approved for various oncology indications. For more details, visit www.karyopharm.com.
Details
News Market Reaction – KPTI
The recorded move for KPTI in the trading session of this news was +3.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Jan. 4, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 41st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT, followed by a question-and-answer breakout session at 10:50 a.m. PT.
A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-present-at-41st-annual-jp-morgan-healthcare-conference-301712627.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.